Early detection of prostate cancer is crucial, when caught early it is very treatable. Potential risk factors such as genetics and family history should be considered when getting screened. Those who are more susceptible may benefit as young as 40.
https://t.co/wVqMG0Rhsg
Compatible with Fusion Bx, Avenda Health's Unfold AI improves staging and treatment planning. The cancer estimation map tool improved diagnosis of seminal vesicle invasion compared to MRI alone. https://t.co/QvVK9dMpxG
At the International Life Symposium in Barcelona, Dr.Nam's presentation featured the Fusion Bx 2.0 with @angiodynamics NanoKnife System. The real-time 3D navigation allows physicians to place IRE electrodes accurately and efficiently to achieve the desired treatment margins.
MRI-targeted biopsies just got even more accessible! With @LucidaMedical Pi software, automatically generated contoured MR images seamlessly integrate with Fusion Bx 2.0, streamlining the process for enhanced precision. Stop by our booth (A46) at #EAU25 for a live demo.
With its seamless integration of 3D navigation, MRI-to-ultrasound fusion, and a stabilized stepper, Fusion Bx 2.0 enables focal therapy when paired with @AngioDynamics NanoKnife. Come visit us at #EAU25 (stand A46) and see for yourself how easy and effective it is to use.
Visit us at Booth A46 to see why the Fusion Bx 2.0 is the complete end-to-end prostate cancer management solution. Proudly designed and manufactured in Canada, the Fusion Bx gives urologists the flexibility to diagnose, plan and treat using the targeted approach. #EAU25
The BBC and Prostate Cancer UK warns about the accuracy of at home PSA tests, many give false positives, or worse, false negatives. For peace of mind, men are encouraged to access these tests through their GP.
https://t.co/orp8ulwLuP
From Urology Times, trends in urology for 2025 include personalized prostate cancer care, workforce shortages, the role of AI in diagnostics and clinical decision making and biomarkers for early detection.
https://t.co/ofR1ruilja
@angiodynamics NanoKnife System receives 510(k) clearance for prostate tissue ablation. Compatible with the Fusion Bx 2.0, the system delivers electrical pulses through specifically placed needles to treat target areas. https://t.co/VLpOpwJLx0
An estimated 1 in 8 Canadian men will develop prostate cancer. Check out what men should know about getting screened for prostate cancer this #Movember https://t.co/xComGEICAr
Treatment doesn't have to be an all or nothing situation. Offer patients more options that preserve quality of life with focal therapy. See how the Fusion Bx 2.0 works seamlessly with @AngioDynamics NanoKnife to perform IRE procedures. https://t.co/DcAdOXVnsw
It's that time of year again to shine a light on the importance of prostate cancer screening. Whether you grow a beard, fundraise or move, there are several ways to spread awareness this #Movember.
https://t.co/XGmNAQ7EML
Our team is proud to be exhibiting with Novomed at the annual #SIU24. Together, we have made the Fusion Bx 2.0 accessible to patients at 3 major hospitals in India: @TataMemorial, @KDAHNaviMumbai and Sir H. N. @RFhospital.
Visit us at the annual SIU (Société Internationale d'Urologie) where we are exhibiting with our distributor Novomed. Stop by to see how the Fusion Bx 2.0 works with the Sonablate for a complete end to end prostate biopsy solution. #SIU24
Findings from the PREVENT Trial provide strong evidence that transperineal biopsies performed under local anesthesia have a lower risk of sepsis compared to transrectal. https://t.co/NQOwGaQwpt
Visit us at FOCAL2024 to see why the Fusion Bx 2.0 is your complete end-to-end prostate biopsy solution. Our system allows physicians to specifically place needles and markers during targeted procedures such as IRE and HIFU. #FOCAL2024
Did you know @Angiodynamics Nanoknife System is compatible with the Fusion Bx 2.0? Our system visualizes the where the needle electrodes are in real time, so physicians can confidently target areas for treatment. Visit us at FOCAL 2024 to learn more. #FOCAL2024
Ontario MPP is calling on the government to cover the cost of PSA testing through OHIP. Screening is an essential step in managing PCa. Currently, Ontario is one of the only provinces that doesn't make the test available under a free healthcare plan. https://t.co/8WBwPhIGpx
Leeds Teaching Hospital Trust is piloting Lucida Medical's Pi software tool for detecting clinically significant cancer on MRIs. Compatible with the Fusion Bx, Pi has the potential to streamline the prostate workflow, allowing men to get biopsied sooner. https://t.co/qyf1Ekw0cD